BDR Pharma launches Bdenza 160 mg for treatment of prostate cancer
Another first time ever launch of Enzalutamide 160 mg in BDR Pharma's basket was awaited by many Indian oncologists
BDR Pharma has launched Enzalutamide with brand name Bdenza in 160mg strength for treating prostate cancer patients. This medicine was previously available in 40 mg and 80 mg strength for which patients had to consume two tablets in a day as per approved dosage that is primarily used to treat such patients, BDR Pharma informed in a statement.
The objective behind the launch of Enzalutamide 160 mg is to ensure better efficacy, minimum side effects, contain relapse cases by blocking the hormones of cancer cells providing an evolved treatment, the statement said.
Another first time ever launch of Enzalutamide 160 mg in BDR Pharma’s basket was awaited by many Indian oncologists. Prostate cancer patients will now have to consume only one tablet in a day, the statement further mentioned.
- Advertisement -